HC Wainwright Reaffirms “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $21.00 price target on the stock.

Several other research analysts have also issued reports on the stock. B. Riley decreased their price target on shares of PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, June 12th. Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.25.

PDS Biotechnology Trading Up 2.0 %

Shares of PDSB stock opened at $3.06 on Tuesday. The stock has a 50-day simple moving average of $3.38 and a 200 day simple moving average of $3.52. The stock has a market capitalization of $112.24 million, a P/E ratio of -2.25 and a beta of 1.88. PDS Biotechnology has a fifty-two week low of $2.53 and a fifty-two week high of $6.85. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same quarter in the prior year, the business posted ($0.37) EPS. On average, sell-side analysts expect that PDS Biotechnology will post -1.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PDS Biotechnology

Several hedge funds have recently made changes to their positions in PDSB. Vanguard Group Inc. grew its position in PDS Biotechnology by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after purchasing an additional 82,135 shares in the last quarter. Blair William & Co. IL grew its holdings in shares of PDS Biotechnology by 204.4% during the second quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after buying an additional 81,743 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in PDS Biotechnology during the second quarter valued at $146,000. Squarepoint Ops LLC acquired a new position in PDS Biotechnology during the second quarter valued at $120,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in PDS Biotechnology in the 2nd quarter worth about $115,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.